Pharmaceuticals industry, Medicine, Healthcare industry, Global health, Inequality Business | The Guardian
Pharmaceutical corporations claim high prices are the cost of innovation, but the reality is far more complicated — and troubling. In 2030, the patents of some of the world’s best-selling drugs will expire, an event called the ‘patent cliff’, and companies are doubling down on tactics such as ‘evergreening’ patents and pay-for-delay deals to keep prices high and competition out.In this video, Neelam Tailor uncovers the shocking strategies big pharma use to game the system, explaining how these moves protect profits but hurt patients Continue reading…
Pharmaceutical corporations claim high prices are the cost of innovation, but the reality is far more complicated — and troubling. In 2030, the patents of some of the world’s best-selling drugs will expire, an event called the ‘patent cliff’, and companies are doubling down on tactics such as ‘evergreening’ patents and pay-for-delay deals to keep prices high and competition out.
In this video, Neelam Tailor uncovers the shocking strategies big pharma use to game the system, explaining how these moves protect profits but hurt patients
